2026-27 COVID vaccine strain selection; LP.8.1 stuck without ACIP; Canadian NACI risk-based guidance; new VE and cardiovascular benefit data; JAMA study published; JN.1/KP.2 antibody similarity; same-day coadministration safety confirmed; 30M cohort shows MACE reduction; new hospitalization risk reduction data for 65+; new dosing guidance for older adults and immunocompromised; systematic review confirms second booster effectiveness in older adults
Key Questions
Which strain was selected for the 2026-27 COVID vaccine?
FDA VRBPAC met June 26 and considered XFG ('Stratus') as the leading candidate due to immune escape and dominance, despite WHO recommending LP.8.1. Manufacturer readiness is confirmed under an annualized model.
What real-world effectiveness data exists for recent COVID vaccines?
2025-26 vaccines showed 55% VE in older adults, 59% hospitalization reduction in 65+, and 41% reduction in critical illness. A 30-million-person study found 65-76% lower MACE risk.
Is same-day coadministration of COVID and flu vaccines safe?
Large VA cohort data confirm no increased adverse events with same-day dosing. This supports fall planning despite ACIP limbo.
What guidance has Canada issued for COVID vaccines?
NACI narrowed recommendations to risk-based targeting for high-risk groups. This contrasts with broader US approaches amid ACIP delays.
Why is the LP.8.1 vaccine stuck without recommendations?
It was approved for 65+ and high-risk groups but lacks ACIP endorsement due to lack of quorum. Insurers may not cover it without a recommendation.
FDA VRBPAC picked XFG ('Stratus') as leading candidate for 2026-27 strain. LP.8.1 vaccine approved for 65+ and high-risk but stuck without ACIP recommendation. COVID-19 is rising in all 50 states; Xocova (ensitrelvir) approved for post-exposure prophylaxis. Canadian NACI narrows to risk-based targeting. New real-world data: 2025-2026 COVID vaccines reduced hospitalization risk by 59% in 65+. 30-million-person cohort study shows COVID-19 vaccination reduces MACE by 65-76%. New dosing guidance: older adults and immunocompromised should receive two COVID-19 doses separated by 6 months. Systematic review confirms second booster effectiveness in older adults. Major FDA policy shift to risk-based COVID boosters (65+ and high-risk via immunogenicity) while demanding RCTs for healthy adults 6mo-64y. Insurers covering vaccines through 2027 per Medpage Today synthesis. ACIP still hasn't met, leaving fall COVID shot recommendations in limbo. Key reassurance from Schaffner: insurers will cover and professional societies are recommending. A Florida summer COVID surge article provides practical guidance on whether to get a booster now or wait for the fall updated vaccine, reinforcing risk-stratified decision-making.